About JENSCARE-B Company

Ningbo Jianshi Technology Co., Ltd. is a medical device company based in China, dedicated to developing interventional products for the treatment of structural heart disease. The company was established in November 2011 in China. Since then, we have developed a range of treatment solutions for different types of structural heart diseases, including tricuspid valve disease, aortic valve disease, mitral valve disease, and heart failure. Our core product, LUX-Valve, has the potential to treat severe tricuspid valve reflux, and according to Frost & Sullivan's data, since LUX-Valve is the world's first product under development to complete the enrollment of test subjects in confirmatory clinical trials, it is expected to be one of the first transcatheter tricuspid valve replacement products approved for commercialization in the world. Furthermore, according to Frost & Sullivan's data, LUX-Valve was recognized as a “breakthrough medical device” under the Breakthrough Medical Device Program by the US Food and Drug Administration in November 2021, making it the first domestic self-developed medical device in the field of valvular heart disease treatment to receive this certification. Our other core product, Ken-Valve, is designed to treat severe aortic valve reflux (or aortic stenosis combined with aortic stenosis) and is expected to meet the needs of more patients, far greater than the transcatheter aortic valve replacement system for which only treatment of aortic stenosis is indicated. We are also developing eight other products with advanced technology, including (i) JenSclip, an innovative transcatheter mitral valve repair clamping system with many unique designs that make it stand out from other transcatheter mitral valve repair systems on the market; (ii) MitraPatch, an innovative transcatheter mitral valve repair product that uses valve repair technology to repair the mitral valve; and a number of advanced products under development for different types of valvular heart disease and heart failure.